Maria Learoyd

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev et al. · The Lancet Oncology · 2018 · 409 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Bert H. O’Neil, Laura W. Goff, John Kauh et al. · Journal of Clinical Oncology · 2011 · 141 citations · Full text

Medicine, Oncology, Pharmacology +17

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEK

Anthony W. Tolcher, Khurum Khan, Michael Ong et al. · Clinical Cancer Research · 2014 · 137 citations · Full text

Medicine, Oncology, Pharmacology +16

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong et al. · Gynecologic Oncology · 2018 · 130 citations

Medicine, Oncology, Pharmacology +16

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

David P. Nicolau, Leonard Siew, J. Armstrong et al. · Journal of Antimicrobial Chemotherapy · 2015 · 129 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +14